reweave: merge 14 files via frontmatter union [auto]

domains/ai-alignment/eu-gpai-requirements-create-extraterritorial-governance-asymmetry-for-us-frontier-labs.md

@@ -19,8 +19,10 @@ related:
 - eu-ai-act-military-exclusion-gap-limits-governance-scope-to-civilian-systems
 supports:
 - EU AI Act GPAI evaluation requirements represent the only surviving mandatory governance mechanism targeting frontier AI after the omnibus deferral because systemic-risk model providers face mandatory evaluation risk assessment and AI Office notification from August 2026 while high-risk deployment requirements were deferred 16-24 months
+- EU GPAI compliance is commercially driven by market access leverage rather than enforcement threat producing minimum-viable documentation compliance
 reweave_edges:
 - EU AI Act GPAI evaluation requirements represent the only surviving mandatory governance mechanism targeting frontier AI after the omnibus deferral because systemic-risk model providers face mandatory evaluation risk assessment and AI Office notification from August 2026 while high-risk deployment requirements were deferred 16-24 months|supports|2026-05-10
+- EU GPAI compliance is commercially driven by market access leverage rather than enforcement threat producing minimum-viable documentation compliance|supports|2026-05-11
 ---
 
 # EU GPAI requirements apply to US frontier AI labs without equivalent domestic US requirements creating a de facto extraterritorial governance asymmetry where AI producers face mandatory EU evaluation that US law does not impose

domains/ai-alignment/multilateral-verification-mechanisms-can-substitute-for-failed-voluntary-commitments-when-binding-enforcement-replaces-unilateral-sacrifice.md

@@ -14,10 +14,12 @@ attribution:
 related:
 - EU AI Act extraterritorial enforcement can create binding governance constraints on US AI labs through market access requirements when domestic voluntary commitments fail
 - Mutually Assured Deregulation makes voluntary AI governance structurally untenable because each actor's restraint creates competitive disadvantage, converting the governance game from cooperation to prisoner's dilemma
+- AI verification limits are invoked as corporate safety arguments in government contract disputes rather than just technical research findings
 reweave_edges:
 - EU AI Act extraterritorial enforcement can create binding governance constraints on US AI labs through market access requirements when domestic voluntary commitments fail|related|2026-04-06
 - Voluntary safety constraints without external enforcement mechanisms are statements of intent not binding governance because aspirational language with loopholes enables compliance theater while preserving operational flexibility|supports|2026-04-07
 - Mutually Assured Deregulation makes voluntary AI governance structurally untenable because each actor's restraint creates competitive disadvantage, converting the governance game from cooperation to prisoner's dilemma|related|2026-04-25
+- AI verification limits are invoked as corporate safety arguments in government contract disputes rather than just technical research findings|related|2026-05-11
 supports:
 - Voluntary safety constraints without external enforcement mechanisms are statements of intent not binding governance because aspirational language with loopholes enables compliance theater while preserving operational flexibility
 ---

domains/grand-strategy/voluntary-ai-safety-constraints-lack-legal-enforcement-mechanism-when-primary-customer-demands-safety-unconstrained-alternatives.md

@@ -16,6 +16,7 @@ reweave_edges:
 - Voluntary safety constraints without external enforcement mechanisms are statements of intent not binding governance because aspirational language with loopholes enables compliance theater while preserving operational flexibility|supports|2026-04-07
 - Legible immediate harm enforces governance convergence independent of competitive incentives because OpenAI implemented access restrictions on GPT-5.5 Cyber identical to Anthropic's Mythos restrictions within weeks of publicly criticizing Anthropic's approach|related|2026-05-05
 - Pentagon exclusion creates EU civilian compliance advantage through pre-aligned safety practices when enforcement proceeds|related|2026-05-05
+- Hard safety constraints backed by litigation survive government coercion where soft voluntary pledges collapse under competitive pressure|related|2026-05-11
 related:
 - voluntary-ai-safety-constraints-lack-legal-enforcement-mechanism-when-primary-customer-demands-safety-unconstrained-alternatives
 - judicial-oversight-of-ai-governance-through-constitutional-grounds-not-statutory-safety-law
@@ -27,6 +28,7 @@ related:
 - independent-ai-evaluation-infrastructure-faces-evaluation-enforcement-disconnect
 - Legible immediate harm enforces governance convergence independent of competitive incentives because OpenAI implemented access restrictions on GPT-5.5 Cyber identical to Anthropic's Mythos restrictions within weeks of publicly criticizing Anthropic's approach
 - Pentagon exclusion creates EU civilian compliance advantage through pre-aligned safety practices when enforcement proceeds
+- Hard safety constraints backed by litigation survive government coercion where soft voluntary pledges collapse under competitive pressure
 ---
 
 # Voluntary AI safety constraints are protected as corporate speech but unenforceable as safety requirements, creating legal mechanism gap when primary demand-side actor seeks safety-unconstrained providers

domains/health/ibogaine-federal-policy-priority-rests-on-single-n30-pilot-illustrating-veteran-constituency-acceleration-ahead-of-evidence-hierarchy.md

@@ -10,9 +10,15 @@ agent: vida
 sourced_from: health/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md
 scope: structural
 sourcer: Stanford University School of Medicine / CNN / NPR
-related: ["healthcare-ai-regulation-needs-blank-sheet-redesign", "the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access"]
+related:
+- healthcare-ai-regulation-needs-blank-sheet-redesign
+- the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access
+supports:
+- Stanford Ibogaine Veterans Study
+reweave_edges:
+- Stanford Ibogaine Veterans Study|supports|2026-05-11
 ---
 
 # Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
 
-The Stanford ibogaine study enrolled 30 veterans with PTSD, TBI, and/or substance use disorder in an overseas clinical setting (ibogaine is Schedule I in the US). At 1-month follow-up, participants self-reported 88% PTSD reduction, 87% depression reduction, and 81% anxiety reduction. The study had no control group, no blinding, single timepoint, and a non-representative veteran population. Despite these severe evidence limitations, Trump's April 2026 executive order specifically named ibogaine for veterans and allocated $50M in ARPA-H funding. Ex-Navy SEALs and Special Operations veterans were present at the EO signing. This represents a case where a small pilot study with compelling effect sizes in a politically salient population (veterans) drove federal policy and funding commitments ahead of the standard evidence hierarchy that would require Phase 2 and Phase 3 trials. The veteran constituency's political influence created a policy pathway that bypassed the usual requirement for controlled trials before major federal investment. This pattern differs from standard psychedelic development (psilocybin, MDMA) where policy follows rather than precedes Phase 3 evidence.
+The Stanford ibogaine study enrolled 30 veterans with PTSD, TBI, and/or substance use disorder in an overseas clinical setting (ibogaine is Schedule I in the US). At 1-month follow-up, participants self-reported 88% PTSD reduction, 87% depression reduction, and 81% anxiety reduction. The study had no control group, no blinding, single timepoint, and a non-representative veteran population. Despite these severe evidence limitations, Trump's April 2026 executive order specifically named ibogaine for veterans and allocated $50M in ARPA-H funding. Ex-Navy SEALs and Special Operations veterans were present at the EO signing. This represents a case where a small pilot study with compelling effect sizes in a politically salient population (veterans) drove federal policy and funding commitments ahead of the standard evidence hierarchy that would require Phase 2 and Phase 3 trials. The veteran constituency's political influence created a policy pathway that bypassed the usual requirement for controlled trials before major federal investment. This pattern differs from standard psychedelic development (psilocybin, MDMA) where policy follows rather than precedes Phase 3 evidence.

domains/health/ibogaine-iv-magnesium-protocol-demonstrates-cardiac-risk-manageable-in-supervised-settings-addressing-primary-safety-barrier.md

@@ -10,9 +10,16 @@ agent: vida
 sourced_from: health/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md
 scope: functional
 sourcer: Stanford University School of Medicine
-related: ["healthcare-ai-regulation-needs-blank-sheet-redesign"]
+related:
+- healthcare-ai-regulation-needs-blank-sheet-redesign
+supports:
+- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
+- Stanford Ibogaine Veterans Study
+reweave_edges:
+- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies|supports|2026-05-11
+- Stanford Ibogaine Veterans Study|supports|2026-05-11
 ---
 
 # IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials
 
-Ibogaine is known to cause QT prolongation, a potentially fatal heart arrhythmia, with more than 30 deaths reported in the medical literature. This cardiac risk has been the primary barrier to clinical development in regulated settings. The Stanford protocol administered ibogaine with intravenous magnesium specifically to protect cardiac rhythm, and all 30 participants were screened for cardiac risk factors before enrollment. The study reported zero serious cardiac events. While n=30 is too small to definitively establish safety, this represents the first published protocol demonstrating that ibogaine's cardiac risk may be manageable through prophylactic intervention and screening in a hospital-grade clinical environment. The IV magnesium approach is a clinical safety innovation that could enable Phase 3 trial design by addressing the primary regulatory safety concern. This shifts ibogaine from 'too dangerous to study' to 'requires specialized protocol' category, similar to how ketamine's dissociative effects required specialized clinical settings but didn't prevent FDA approval for depression.
+Ibogaine is known to cause QT prolongation, a potentially fatal heart arrhythmia, with more than 30 deaths reported in the medical literature. This cardiac risk has been the primary barrier to clinical development in regulated settings. The Stanford protocol administered ibogaine with intravenous magnesium specifically to protect cardiac rhythm, and all 30 participants were screened for cardiac risk factors before enrollment. The study reported zero serious cardiac events. While n=30 is too small to definitively establish safety, this represents the first published protocol demonstrating that ibogaine's cardiac risk may be manageable through prophylactic intervention and screening in a hospital-grade clinical environment. The IV magnesium approach is a clinical safety innovation that could enable Phase 3 trial design by addressing the primary regulatory safety concern. This shifts ibogaine from 'too dangerous to study' to 'requires specialized protocol' category, similar to how ketamine's dissociative effects required specialized clinical settings but didn't prevent FDA approval for depression.

domains/health/mdma-assisted-therapy-functional-unblinding-invalidates-self-reported-outcomes-despite-phase3-efficacy.md

@@ -10,9 +10,14 @@ agent: vida
 sourced_from: health/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md
 scope: structural
 sourcer: FDA / Psychiatric Times / STAT News
-related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software"]
+related:
+- prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software
+supports:
+- Psychedelic therapy regulatory approval requires either active comparator designs or objective endpoints because highly psychoactive compounds create functional unblinding that invalidates self-reported psychiatric outcomes
+reweave_edges:
+- Psychedelic therapy regulatory approval requires either active comparator designs or objective endpoints because highly psychoactive compounds create functional unblinding that invalidates self-reported psychiatric outcomes|supports|2026-05-11
 ---
 
 # MDMA-assisted therapy's FDA rejection reveals that clinical efficacy is necessary but insufficient for regulatory approval when functional unblinding invalidates self-reported outcomes in psychiatry trials
 
-The FDA rejected Lykos Therapeutics' MDMA-assisted therapy for PTSD despite statistically significant Phase 3 efficacy (MAPP1 and MAPP2 trials showed CAPS-5 score reductions). The rejection centered on functional unblinding: MDMA's pronounced empathogenic and euphoric effects mean participants reliably know whether they received active drug or placebo. The FDA Psychopharmacologic Drugs Advisory Committee voted 10-1 that functional unblinding compromised trial validity—essentially unanimous agreement that MDMA trials cannot use inert placebo controls. This is a STRUCTURAL problem, not fixable through protocol modifications. The FDA explicitly required an additional Phase 3 study, indicating the existing evidence base was methodologically invalid despite clinical benefit. The contrast with psilocybin is instructive: Compass Pathways used 1mg as active placebo comparator (visually and experientially distinct from 25mg therapeutic dose) rather than inert placebo, and their Phase 3 trials passed FDA scrutiny. The divergence reveals that regulatory success depends not just on efficacy but on trial methodology that preserves outcome validity. For psychiatry trials relying on self-reported outcomes, functional unblinding creates systematic bias that invalidates results regardless of true clinical benefit.
+The FDA rejected Lykos Therapeutics' MDMA-assisted therapy for PTSD despite statistically significant Phase 3 efficacy (MAPP1 and MAPP2 trials showed CAPS-5 score reductions). The rejection centered on functional unblinding: MDMA's pronounced empathogenic and euphoric effects mean participants reliably know whether they received active drug or placebo. The FDA Psychopharmacologic Drugs Advisory Committee voted 10-1 that functional unblinding compromised trial validity—essentially unanimous agreement that MDMA trials cannot use inert placebo controls. This is a STRUCTURAL problem, not fixable through protocol modifications. The FDA explicitly required an additional Phase 3 study, indicating the existing evidence base was methodologically invalid despite clinical benefit. The contrast with psilocybin is instructive: Compass Pathways used 1mg as active placebo comparator (visually and experientially distinct from 25mg therapeutic dose) rather than inert placebo, and their Phase 3 trials passed FDA scrutiny. The divergence reveals that regulatory success depends not just on efficacy but on trial methodology that preserves outcome validity. For psychiatry trials relying on self-reported outcomes, functional unblinding creates systematic bias that invalidates results regardless of true clinical benefit.

domains/health/psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability.md

@@ -10,10 +10,18 @@ agent: vida
 sourced_from: health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md
 scope: causal
 sourcer: Compass Pathways
-challenges: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software"]
-related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse"]
+challenges:
+- prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software
+related:
+- the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access
+- prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software
+- antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse
+supports:
+- Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation
+reweave_edges:
+- Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation|supports|2026-05-11
 ---
 
 # Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
 
-The COMP005 trial achieved its primary endpoint with a statistically significant MADRS improvement of -3.6 points versus placebo (95% CI [-5.7, -1.5], p<0.001) at week 6 in 258 participants with treatment-resistant depression. The effect size is comparable to existing TRD augmentation strategies (typically 2-4 MADRS points) but with a fundamentally different dosing paradigm: a single administration producing benefits that persist through 26 weeks. This durability from a single dose represents a paradigm shift from the daily-dosing chronic treatment model that defines current psychiatric pharmacotherapy. The trial embedded psychological support as a required protocol component (preparation, session monitoring, integration), indicating that psilocybin therapy is a hybrid clinical intervention combining pharmacological mechanism (5-HT2A agonism) with structured psychological process. Safety profile showed all adverse events were mild-to-moderate and resolved within 24 hours, with no clinically meaningful difference in suicidal ideation between arms. This is the first investigational psychedelic to report positive Phase 3 data, establishing proof-of-concept for FDA approval of a classic psychedelic and creating a regulatory pathway for the broader class. The treatment-resistant depression population (7M Americans who have failed 2+ antidepressant courses) represents a clinical need where existing medicine has limited options, making this a genuine expansion of the treatment toolkit rather than incremental improvement.
+The COMP005 trial achieved its primary endpoint with a statistically significant MADRS improvement of -3.6 points versus placebo (95% CI [-5.7, -1.5], p<0.001) at week 6 in 258 participants with treatment-resistant depression. The effect size is comparable to existing TRD augmentation strategies (typically 2-4 MADRS points) but with a fundamentally different dosing paradigm: a single administration producing benefits that persist through 26 weeks. This durability from a single dose represents a paradigm shift from the daily-dosing chronic treatment model that defines current psychiatric pharmacotherapy. The trial embedded psychological support as a required protocol component (preparation, session monitoring, integration), indicating that psilocybin therapy is a hybrid clinical intervention combining pharmacological mechanism (5-HT2A agonism) with structured psychological process. Safety profile showed all adverse events were mild-to-moderate and resolved within 24 hours, with no clinically meaningful difference in suicidal ideation between arms. This is the first investigational psychedelic to report positive Phase 3 data, establishing proof-of-concept for FDA approval of a classic psychedelic and creating a regulatory pathway for the broader class. The treatment-resistant depression population (7M Americans who have failed 2+ antidepressant courses) represents a clinical need where existing medicine has limited options, making this a genuine expansion of the treatment toolkit rather than incremental improvement.

domains/health/psychedelic-therapy-regulatory-success-requires-active-comparator-or-objective-endpoints-for-highly-psychoactive-compounds.md

@@ -10,8 +10,17 @@ agent: vida
 sourced_from: health/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md
 scope: structural
 sourcer: FDA / Psychiatric Times / STAT News
+supports:
+- MDMA-assisted therapy's FDA rejection reveals that clinical efficacy is necessary but insufficient for regulatory approval when functional unblinding invalidates self-reported outcomes in psychiatry trials
+related:
+- Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
+- Psilocybin therapy requires psychological support as an embedded clinical protocol component not an optional adjunct
+reweave_edges:
+- MDMA-assisted therapy's FDA rejection reveals that clinical efficacy is necessary but insufficient for regulatory approval when functional unblinding invalidates self-reported outcomes in psychiatry trials|supports|2026-05-11
+- Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic|related|2026-05-11
+- Psilocybin therapy requires psychological support as an embedded clinical protocol component not an optional adjunct|related|2026-05-11
 ---
 
 # Psychedelic therapy regulatory approval requires either active comparator designs or objective endpoints because highly psychoactive compounds create functional unblinding that invalidates self-reported psychiatric outcomes
 
-The FDA's rejection of MDMA-assisted therapy while psilocybin trials advance reveals a critical design constraint: the intensity of psychoactive effects determines viable trial methodology. MDMA produces pronounced empathogenic and euphoric effects that make functional unblinding inevitable with inert placebo—participants know they received the drug. The FDA advisory committee's 10-1 vote established this as disqualifying for self-reported psychiatric outcomes. In contrast, Compass Pathways' psilocybin trials used 1mg as active comparator (producing some perceptual effects) versus 25mg therapeutic dose, addressing the blinding concern through dose differentiation rather than inert placebo. This design choice allowed psilocybin trials to pass FDA scrutiny that MDMA trials failed. The implication generalizes: any highly psychoactive compound faces the same structural challenge. Future trials must either use active comparators that preserve some degree of blinding, or shift to objective endpoints (biomarkers, clinician-rated outcomes, behavioral measures) that are less vulnerable to expectancy bias. The functional unblinding problem is not solvable through protocol refinements—it requires fundamental redesign of trial architecture based on the compound's psychoactive profile.
+The FDA's rejection of MDMA-assisted therapy while psilocybin trials advance reveals a critical design constraint: the intensity of psychoactive effects determines viable trial methodology. MDMA produces pronounced empathogenic and euphoric effects that make functional unblinding inevitable with inert placebo—participants know they received the drug. The FDA advisory committee's 10-1 vote established this as disqualifying for self-reported psychiatric outcomes. In contrast, Compass Pathways' psilocybin trials used 1mg as active comparator (producing some perceptual effects) versus 25mg therapeutic dose, addressing the blinding concern through dose differentiation rather than inert placebo. This design choice allowed psilocybin trials to pass FDA scrutiny that MDMA trials failed. The implication generalizes: any highly psychoactive compound faces the same structural challenge. Future trials must either use active comparators that preserve some degree of blinding, or shift to objective endpoints (biomarkers, clinician-rated outcomes, behavioral measures) that are less vulnerable to expectancy bias. The functional unblinding problem is not solvable through protocol refinements—it requires fundamental redesign of trial architecture based on the compound's psychoactive profile.

domains/health/trump-2026-psychedelic-executive-order-creates-bipartisan-regulatory-acceleration-through-existing-frameworks.md

@@ -10,10 +10,17 @@ agent: vida
 sourced_from: health/2026-04-18-trump-executive-order-psychedelics-mental-health.md
 scope: structural
 sourcer: White House / FDA
-challenges: ["healthcare-ai-regulation-needs-blank-sheet-redesign"]
-related: ["healthcare-ai-regulation-needs-blank-sheet-redesign", "fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness"]
+challenges:
+- healthcare-ai-regulation-needs-blank-sheet-redesign
+related:
+- healthcare-ai-regulation-needs-blank-sheet-redesign
+- fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness
+supports:
+- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
+reweave_edges:
+- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies|supports|2026-05-11
 ---
 
 # Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation
 
-The Executive Order issued April 18, 2026 creates three procedural accelerations for psychedelic drug development: (1) FDA National Priority Vouchers issued to Compass Pathways (COMP360 psilocybin), Usona Institute (psilocybin), and Transcend Therapeutics (methylone TSND-201) compress review timelines to 1-2 months post-application; (2) FDA and DEA directed to establish Right to Try pathway for psilocybin and ibogaine, allowing pre-approval access for seriously ill patients; (3) $50 million ARPA-H funding to match state investments in psychedelic research, specifically naming ibogaine for veterans. Critically, the EO does NOT change Schedule I status, does NOT approve any drug, and does NOT create enforceable patient rights—it operates entirely within existing regulatory frameworks. The political significance is structural: a Republican administration accelerating Schedule I drug pathways represents bipartisan momentum driven by veteran advocacy groups (ex-Navy SEALs present at signing ceremony). This de-risks clinical investment by providing procedural clarity and expedited review pathways without requiring legislative change. The FDA responded within 6 days by issuing the three priority vouchers, demonstrating immediate implementation. The regulatory posture shift is from experimental-to-expedited rather than prohibited-to-permitted.
+The Executive Order issued April 18, 2026 creates three procedural accelerations for psychedelic drug development: (1) FDA National Priority Vouchers issued to Compass Pathways (COMP360 psilocybin), Usona Institute (psilocybin), and Transcend Therapeutics (methylone TSND-201) compress review timelines to 1-2 months post-application; (2) FDA and DEA directed to establish Right to Try pathway for psilocybin and ibogaine, allowing pre-approval access for seriously ill patients; (3) $50 million ARPA-H funding to match state investments in psychedelic research, specifically naming ibogaine for veterans. Critically, the EO does NOT change Schedule I status, does NOT approve any drug, and does NOT create enforceable patient rights—it operates entirely within existing regulatory frameworks. The political significance is structural: a Republican administration accelerating Schedule I drug pathways represents bipartisan momentum driven by veteran advocacy groups (ex-Navy SEALs present at signing ceremony). This de-risks clinical investment by providing procedural clarity and expedited review pathways without requiring legislative change. The FDA responded within 6 days by issuing the three priority vouchers, demonstrating immediate implementation. The regulatory posture shift is from experimental-to-expedited rather than prohibited-to-permitted.

domains/internet-finance/genius-act-public-company-restriction-creates-asymmetric-big-tech-barrier-while-permitting-private-non-financial-issuers.md

@@ -12,9 +12,11 @@ sourcer: Nellie Liang, Brookings Institution
 related:
 - GENIUS Act freeze/seize requirement creates mandatory control surface that conflicts with autonomous smart contract payment coordination
 - GENIUS Act reserve custody rules create indirect banking system dependency for nonbank stablecoin issuers without requiring bank charter
+- GENIUS Act stablecoin yield prohibition reveals rent-protection motive because White House economists find negligible lending protection ($2.1B baseline, $531B worst-case) while consumers lose $800M annually in forgone yield
 reweave_edges:
 - GENIUS Act freeze/seize requirement creates mandatory control surface that conflicts with autonomous smart contract payment coordination|related|2026-04-18
 - GENIUS Act reserve custody rules create indirect banking system dependency for nonbank stablecoin issuers without requiring bank charter|related|2026-04-18
+- GENIUS Act stablecoin yield prohibition reveals rent-protection motive because White House economists find negligible lending protection ($2.1B baseline, $531B worst-case) while consumers lose $800M annually in forgone yield|related|2026-05-11
 ---
 
 # GENIUS Act public company restriction creates asymmetric Big Tech barrier while permitting private non-financial issuers

domains/internet-finance/genius-act-reserve-custody-creates-indirect-banking-dependency-for-nonbank-stablecoin-issuers.md

@@ -15,10 +15,12 @@ supports:
 related:
 - GENIUS Act freeze/seize requirement creates mandatory control surface that conflicts with autonomous smart contract payment coordination
 - genius-act-public-company-restriction-creates-asymmetric-big-tech-barrier-while-permitting-private-non-financial-issuers
+- GENIUS Act stablecoin yield prohibition reveals rent-protection motive because White House economists find negligible lending protection ($2.1B baseline, $531B worst-case) while consumers lose $800M annually in forgone yield
 reweave_edges:
 - GENIUS Act freeze/seize requirement creates mandatory control surface that conflicts with autonomous smart contract payment coordination|related|2026-04-18
 - genius-act-public-company-restriction-creates-asymmetric-big-tech-barrier-while-permitting-private-non-financial-issuers|related|2026-04-18
 - national-trust-charters-enable-crypto-exchanges-to-bypass-congressional-gridlock-through-federal-banking-infrastructure|supports|2026-04-18
+- GENIUS Act stablecoin yield prohibition reveals rent-protection motive because White House economists find negligible lending protection ($2.1B baseline, $531B worst-case) while consumers lose $800M annually in forgone yield|related|2026-05-11
 ---
 
 # GENIUS Act reserve custody rules create indirect banking system dependency for nonbank stablecoin issuers without requiring bank charter

domains/space-development/amazon-kuiper-selective-governance-participation-reveals-strategic-preference-for-flexible-principles-over-mandatory-operational-rules.md

@@ -10,9 +10,15 @@ agent: astra
 sourced_from: space-development/2026-05-10-spacenews-amazon-kuiper-wef-guidelines-governance-pattern.md
 scope: functional
 sourcer: LightReading / About Amazon
-related: ["spacex-refusal-to-endorse-wef-debris-governance-instantiates-voluntary-governance-failure-in-orbital-commons", "fcc-orbital-debris-governance-applies-competitive-market-logic-to-commons-externality-problem"]
+related:
+- spacex-refusal-to-endorse-wef-debris-governance-instantiates-voluntary-governance-failure-in-orbital-commons
+- fcc-orbital-debris-governance-applies-competitive-market-logic-to-commons-externality-problem
+supports:
+- SpaceX and Amazon Kuiper non-endorsement of WEF debris guidelines demonstrates systemic voluntary governance failure at the scale where it matters most
+reweave_edges:
+- SpaceX and Amazon Kuiper non-endorsement of WEF debris guidelines demonstrates systemic voluntary governance failure at the scale where it matters most|supports|2026-05-11
 ---
 
 # Amazon Kuiper selective governance participation reveals strategic preference for flexible principles-based frameworks over mandatory operational rules
 
-Amazon Kuiper's governance participation pattern reveals a deliberate strategy of selective engagement: the company joined ESA's Zero Debris Charter (principles-based voluntary framework) while actively requesting the FCC to drop the five-year deorbit rule (the primary binding US orbital debris mitigation instrument) and declining to endorse the WEF guidelines. This is not simple non-participation but governance arbitrage—participating in flexible, principles-based frameworks that allow operational discretion while resisting specific, operationally constraining mandatory rules. Amazon argues the FCC rule creates operational constraints that could be better addressed through propulsion-based active maneuvering, but the effect of eliminating the 5-year deorbit rule would be longer satellite lifetimes and potentially greater debris accumulation risk without active debris removal. The pattern mirrors SpaceX's selective regulatory engagement (supporting FCC reporting requirements while declining WEF). Both companies are optimizing for governance that constrains competitors while preserving their own operational flexibility. This demonstrates that when given a choice between binding operational constraints and voluntary principles, rational actors with large constellations will systematically choose the latter.
+Amazon Kuiper's governance participation pattern reveals a deliberate strategy of selective engagement: the company joined ESA's Zero Debris Charter (principles-based voluntary framework) while actively requesting the FCC to drop the five-year deorbit rule (the primary binding US orbital debris mitigation instrument) and declining to endorse the WEF guidelines. This is not simple non-participation but governance arbitrage—participating in flexible, principles-based frameworks that allow operational discretion while resisting specific, operationally constraining mandatory rules. Amazon argues the FCC rule creates operational constraints that could be better addressed through propulsion-based active maneuvering, but the effect of eliminating the 5-year deorbit rule would be longer satellite lifetimes and potentially greater debris accumulation risk without active debris removal. The pattern mirrors SpaceX's selective regulatory engagement (supporting FCC reporting requirements while declining WEF). Both companies are optimizing for governance that constrains competitors while preserving their own operational flexibility. This demonstrates that when given a choice between binding operational constraints and voluntary principles, rational actors with large constellations will systematically choose the latter.

entities/health/stanford-ibogaine-veterans-study.md

@@ -4,6 +4,12 @@ entity_type: research_program
 name: Stanford Ibogaine Veterans Study
 domain: health
 status: completed
+supports:
+- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
+- IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials
+reweave_edges:
+- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies|supports|2026-05-11
+- IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials|supports|2026-05-11
 ---
 
 # Stanford Ibogaine Veterans Study

entities/internet-finance/genius-act.md

@@ -21,10 +21,12 @@ related:
 - GENIUS Act freeze/seize requirement creates mandatory control surface that conflicts with autonomous smart contract payment coordination
 - genius-act-public-company-restriction-creates-asymmetric-big-tech-barrier-while-permitting-private-non-financial-issuers
 - GENIUS Act reserve custody rules create indirect banking system dependency for nonbank stablecoin issuers without requiring bank charter
+- GENIUS Act stablecoin yield prohibition reveals rent-protection motive because White House economists find negligible lending protection ($2.1B baseline, $531B worst-case) while consumers lose $800M annually in forgone yield
 reweave_edges:
 - GENIUS Act freeze/seize requirement creates mandatory control surface that conflicts with autonomous smart contract payment coordination|related|2026-04-18
 - genius-act-public-company-restriction-creates-asymmetric-big-tech-barrier-while-permitting-private-non-financial-issuers|related|2026-04-18
 - GENIUS Act reserve custody rules create indirect banking system dependency for nonbank stablecoin issuers without requiring bank charter|related|2026-04-18
+- GENIUS Act stablecoin yield prohibition reveals rent-protection motive because White House economists find negligible lending protection ($2.1B baseline, $531B worst-case) while consumers lose $800M annually in forgone yield|related|2026-05-11
 ---
 
 # GENIUS Act (Guiding and Establishing National Innovation for U.S. Stablecoins of 2025)